TABLE 1.
Baseline clinical and demographic characteristics of secondary–progressive multiple sclerosis patients included in AHSCT and matched Cy groups
| Characteristic | AHSCT, n = 31, mean (SD) | Cy, n = 62, mean (SD) | p |
|---|---|---|---|
| Age, years | 39.3 (7.27) | 42.8 (7.09) | 0.029 |
| Disease duration, years | 13.7 (5.28) | 13.8 (6.73) | 0.963 |
| Progressive phase duration, years | 3.6 (2.67) | 2.7 (3.55) | 0.225 |
| Previous treatment duration, years | 8.5 (5.43) | 6.9 (4.76) | 0.174 |
| Previous DMTs, n | 3.0 (1.30) | 1.3 (0.99) | <0.001 |
| Annualized relapse rate in the previous 2 years | 0.56 (0.63) | 0.46 (0.44) | 0.409 |
| Progression index pretreatment | 0.49 (0.18) | 0.64 (0.79) | 0.151 |
| EDSS | 5.9 (0.87) | 5.7 (1.01) | 0.392 |
| Year of treatment | 2009 (5.6) | 2007 (5.2) | 0.112 |
| n (%) | n (%) | p | |
|---|---|---|---|
| Sex, female | 23 (74%) | 38 (61%) | 0.217 |
| Cases with ≥1 relapse over the previous 2 years | 17 (55%) | 41 (66%) | 0.289 |
| Cases naïve to treatment | 0 (0%) | 11 (18%) | 0.013 |
| Cases who had received highly active DMTs | 13 (42%) | 3 (5%) | 0.0001 |
Highly active DMTs include the following: fingolimod, natalizumab, rituximab.
Abbreviations: AHSCT, autologous haematopoietic stem cell transplantation; Cy, cyclophosphamide; DMT, disease‐modifying treatment; EDSS, Expanded Disability Status Scale.